← All trials
NCT05248802
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Apr 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Feb 21, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dexa Medica GroupLead sponsor
- Budhi Asih Hospital, East Jakarta, IndonesiaOverall official - principal investigator
- Pasar Rebo Hospital, South Jakarta, IndonesiaOverall official - principal investigator
- University of IndonesiaOverall official - principal investigator
- Budhi Asih Hospital, East Jakarta, IndonesiaOfficial
- University of IndonesiaOfficial
- Pasar Rebo Hospital, South Jakarta, IndonesiaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.